Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression

被引：0
|
作者：
Rosenberg, J. [1 ]
Necchi, A. [2 ]
Sweis, R. F. [3 ]
Nakajima, K. [4 ]
Lu, C. [5 ]
Nogai, H. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Ist Nazl Tumori Milano Fdn IRCCS, Med Oncol, Milan, Italy
[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Bayer HealthCare Pharmaceut, Clin Dev, Whippany, NJ USA
[5] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA
[6] Bayer AG, Oncol, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
925TiP
引用
收藏
页码：329 / 329
页数：1
相关论文
共 50 条
  • [41] A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
    Lieu, Christopher H.
    Hidalgo, Manuel
    Berlin, Jordan D.
    Ko, Andrew H.
    Cervantes, Andres
    Lorusso, Patricia
    Gerber, David E.
    Eder, J. Paul
    Eckhardt, S. Gail
    Kapp, Amy V.
    Tsuhako, Amy
    Mccall, Bruce
    Pirzkall, Andrea
    Uyei, Anne
    Tabernero, Josep
    ONCOLOGIST, 2017, 22 (09): : 1024 - +
  • [42] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
    Jain, Rohit K.
    Yang, Yuanquan
    Chadha, Juskaran
    Zhang, Jingsong
    Raymond, Sarah
    Oschmann, Erika
    Poehlman, Trey
    Fan, Wenyi
    Kim, Youngchul
    Dhillon, Jasreman
    Chahoud, Jad
    Chatwal, Monica Sheila
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS713 - TPS713
  • [43] BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
    Rosenberg, J. E.
    Bajorin, D. F.
    Smith, A.
    D'Cruz, C.
    Lanasa, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
    Petrylak, Daniel P.
    Tagawa, Scott T.
    Jain, Rohit K.
    Bupathi, Manojkumar
    Balar, Arjun
    Kalebasty, Arash Rezazadeh
    George, Saby
    Palmbos, Phillip
    Nordquist, Luke
    Davis, Nancy
    Ramamurthy, Chethan
    Sternberg, Cora N.
    Loriot, Yohann
    Agarwal, Neeraj
    Park, Chandler
    Tonelli, Julia
    Vance, Morganna
    Zhou, Huafeng
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [45] Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
    Font, A
    Esteban, E
    Carles, J
    Climent, MA
    Gonzalez-Larriba, JL
    Berrocal, A
    Bellmunt, J
    Garcia-Ribas, I
    Marfa, X
    Fabregat, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 392S - 392S
  • [46] Phase ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer
    Hu, Xingsheng
    Han, Xiaohong
    Zhang, Li
    Ding, Yanhua
    Wang, Hanping
    Mu, Hua
    Sun, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer
    Davis, Andrew A.
    Hernandez-Aya, Leonel
    Luo, Jingqin
    Opyrchal, Mateusz
    Ademuyiwa, Foluso O.
    Bagegni, Nusayba A.
    Clifton, Katherine K.
    Anderson, Jill
    Hammerschmidt, Trish
    Nehring, Leslie
    DeNardo, David
    Watson, Mark
    Aft, Rebecca
    Ma, Cynthia
    Weilbaecher, Katherine
    CANCER RESEARCH, 2023, 83 (05)
  • [48] A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer
    Cho, EK
    Lee, WK
    Im, SA
    Lee, SN
    Park, SH
    Bang, SM
    Park, DK
    Park, YH
    Shin, DB
    Lee, JH
    ONCOLOGY, 2005, 68 (4-6) : 333 - 340
  • [49] A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
    Goh, Jeffrey
    Gao, Ben
    Markman, Ben
    Gan, Hui
    Voskoboynik, Mark
    Wu, Yi-Long
    Guo, Jun
    Zhou, Qing
    Zhao, Jun
    Chen, Cheng
    Qiu, Jingjun
    Xu, Yingying
    Yang, Liu
    Millward, Michael
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)
    Y J Choi
    S H Lee
    J-L Lee
    J-H Ahn
    K-H Lee
    D You
    B Hong
    J H Hong
    H Ahn
    British Journal of Cancer, 2015, 112 : 260 - 265
12345